• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Repeated intravenous infusion of mesenchymal stem cells for enhanced functional recovery in a rat model of chronic cerebral ischemia
CONCLUSIONS: These results indicate that repeated systemic administration of MSCs over 3 weeks resulted in greater functional improvement as compared to single administration and/or vehicle infusion. In addition, administration of MSCs is associated with promotion of interhemispheric connectivity through the CC in the chronic phase of cerebral infarction.PMID:34861644 | DOI:10.3171/2021.8.JNS21687
Source: Journal of Neurosurgery - December 3, 2021 Category: Neurosurgery Authors: Mitsuhiro Takemura Masanori Sasaki Yuko Kataoka-Sasaki Ryo Kiyose Hiroshi Nagahama Shinichi Oka Ryo Ukai Takahiro Yokoyama Jeffery D Kocsis Tetsuya Ueba Osamu Honmou Source Type: research

Prevention of neointimal hyperplasia induced by an endovascular stent via intravenous infusion of mesenchymal stem cells.
CONCLUSIONS: Intravenous infusion of MSCs inhibited the inflammatory reaction to an implanted stent strut, and prevented progressive neointimal hyperplasia in the stented CCA and SCA in a porcine model. Thus, MSC treatment could attenuate the recurrence of cerebral ischemic events after stenting. PMID: 31585431 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - October 3, 2019 Category: Neurosurgery Authors: Nakazaki M, Oka S, Sasaki M, Kataoka-Sasaki Y, Onodera R, Komatsu K, Iihoshi S, Hiroura M, Kawaguchi A, Kocsis JD, Honmou O Tags: J Neurosurg Source Type: research

Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study.
CONCLUSIONSIn this completed 2-year phase 1/2a study, implantation of SB623 cells in patients with stable chronic stroke was safe and was accompanied by improvements in clinical outcomes.Clinical trial registration no.: NCT01287936 (clinicaltrials.gov). PMID: 30497166 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - November 1, 2018 Category: Neurosurgery Tags: J Neurosurg Source Type: research

Intravenous infusion of mesenchymal stem cells promotes functional recovery in a rat model of chronic cerebral infarction.
CONCLUSIONSThese results indicate that the systemic infusion of MSCs results in functional improvement, which is associated with structural changes in the chronic phase of cerebral infarction, including in the stabilization of the BBB. PMID: 30485210 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - October 1, 2018 Category: Neurosurgery Tags: J Neurosurg Source Type: research

Intravenous infusion of mesenchymal stem cells for protection against brainstem infarction in a persistent basilar artery occlusion model in the adult rat.
CONCLUSIONSInfused MSCs may provide neuroprotection to facilitate functional outcomes and reduce ischemic lesion volume as evaluated in a newly developed rat model of persistent BAO. PMID: 30485204 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - October 1, 2018 Category: Neurosurgery Tags: J Neurosurg Source Type: research

Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats.
CONCLUSIONS Infused MSCs may inhibit endothelial dysfunction to suppress hemorrhagic events and facilitate functional outcome. Combined therapy of infused MSCs after rtPA therapy facilitated early behavioral recovery. PMID: 28059661 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - January 5, 2017 Category: Neurosurgery Authors: Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Oka S, Namioka T, Namioka A, Onodera R, Suzuki J, Sasaki Y, Nagahama H, Mikami T, Wanibuchi M, Kocsis JD, Honmou O Tags: J Neurosurg Source Type: research